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ABSTRACT
Objectives: To characterize the differences in utility scores
(dUTY) among four commonly used preference-based
Health-Related Quality of Life instruments, to evaluate the
potential impact of these differences on cost-utility analyses
(CUA), and to determine if sociodemographic/clinical factors
inﬂuenced the magnitude of these differences.
Methods: Consenting adult Chinese, Malay and Indian sub-
jects in Singapore were interviewed using Singapore English,
Chinese, Malay or Tamil versions of the EQ-5D, Health
Utilities Index Mark 2 (HUI2) and Mark 3 (HUI3), and
SF-6D. Agreement between instruments was assessed using
Bland–Altman (BA) plots. Changes in incremental cost-utility
ratio (ICUR) from dUTY were investigated using eight hypo-
thetical decision trees. The inﬂuence of sociodemographic/
clinical factors on dUTY between instrument pairs was
studied using multiple linear regression (MLR) models for
English-speaking subjects (circumventing structural zero
issues).
Results: In 667 subjects (median age 48 years, 59% female),
median utility scores ranged from 0.80 (95% conﬁdence
interval [CI] 0.80, 0.85) for the EQ-5D to 0.89 (95% CI
0.88, 0.89) for the SF-6D. BA plots: Mean differences (95%
CI) exceeded the clinically important difference (CID) of 0.04
for four of six pairwise comparisons, with the exception of
the HUI2/EQ-5D (0.03, CI: 0.02, 0.04) and SF-6D/HUI2
(0.02, CI: 0.006, 0.02). Decision trees: The ICER ranged
from $94,661/QALY (quality-adjusted life-year; 6.3% differ-
ence from base case) to $100,693/QALY (0.3% difference
from base case). MLR: Chronic medical conditions, marital
status, and Family Functioning Measures scores signiﬁcantly
(P-value < 0.05) inﬂuenced dUTY for several instrument
pairs.
Conclusion: Although CIDs in utility measurements were
present for different preference-based instruments, the
impact of these differences on CUA appeared relatively
minor. Chronic medical conditions, marital status, and family
functioning inﬂuenced the magnitude of these differences.
Keywords: Asia, comparative study, cost beneﬁt, decision
trees, quality-adjusted life-year.
Introduction
Utility assessment of the health status experienced by
patients is an important part of cost-utility analyses
(CUA), which have been recommended for use in eco-
nomic evaluations of health-care interventions [1,2]. In
CUA, a utility score is assigned to the health state on
the conventional scale in which dead = 0 and perfect
health = 1 to indicate their preferences for different
health outcomes. This utility score is incorporated into
a quality-adjusted life-year (QALY), which combines,
in a single index, gains or losses in quantity (life
expectancy) and quality of life (health utilities) [3].
Utilities may be assessed directly using a variety of
techniques, but are more commonly assessed indirectly
using preference-based Health-Related Quality of Life
(HRQoL) instruments, including the EQ-5D [4],
Health Utilities Index Mark 2 (HUI2) and Mark 3
(HUI3) [5], and SF-6D [6].
Estimates of utilities in CUA may be derived from
meta-analyses of published literature [7]. The validity
of using such estimates from these meta-analyses is,
however, dependant on how comparable the patients
and clinical settings in the studies synthesized are to
the study into which those utility scores will be incor-
porated. In addition, results often differ systematically
depending on the choice of preference-based instru-
ments used to provide utilities in these studies.
Research has shown that there are clinically important
differences (CIDs) in utilities obtained using various
preference-based instruments [8–11]. For example, in
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a sample of patients with rheumatoid arthritis, agree-
ment among the EQ-5D, HUI2, HUI3, and SF-6D was
poor at lower utility values [8]. Utility scores were
highest for HUI2 (median 0.75, interquartile range
0.28) and lowest for HUI3 (0.56, 0.44). Differences in
median utility scores exceeded the CID (see details in
Statistical Analyses) and were largest between HUI2
and HUI3 (0.19) and smallest between HUI2 and
EQ-5D (0.01). In a comparison of the EQ-5D, HUI3,
Quality of Well Being, and SF-6D scores across four
hypothetical health states, SF-6D utilities scores were
highest for all [12]. The differences in utility scores
(dUTY) between SF-6D and the instrument giving the
lowest utility score were again clinically important,
ranging from 0.14 (Quality of Well Being Index; most
severe of four health states) to 0.54 (HUI3; the second
least severe). Thus, utility estimates obtained from
meta-analyses based on studies using a variety of
preference-based instruments may be affected by the
choice of instrument(s). The magnitude of this is illus-
trated by a review of 97 studies where utility estimates
were varied using sensitivity analyses. In 29 (31%) of
these studies, varying the utility estimates resulted in a
reversal of decisions such that a treatment previously
considered acceptable for adoption became unaccept-
able after sensitivity analyses were performed [13].
This study illustrates the importance of the quality and
consistency of point estimates used in CUA.
To address the issue of comparability of utility
scores obtained using different instruments, two
approaches are possible. The ﬁrst is to incorporate
data only from those studies using identical preference-
based instruments. Nevertheless, the number of studies
using identical instruments in similar patient popula-
tions is likely to be small and the generalizability of the
pooled estimate would thus be limited. The second
approach is to quantify and adjust for any differences
among preference-based instruments in which one
instrument consistently overestimates or underesti-
mates utilities relative to another instrument.
In addition, it would be relevant to determine if
sociodemographic and other factors inﬂuenced the
magnitude of these differences as such inﬂuences, if
present, might need to be adjusted for in CUA. There
is good reason to suggest that these factors may inﬂu-
ence the dUTY measured by different instruments. For
example, studies have shown that older adults report
less negative emotion in general and less anger in
response to interpersonal problems than do younger
adults [14–16]. Given that different aspects of emotion
are assessed by different HRQoL instruments (negative
emotions: EQ-5D and SF-6D; positive and nega-
tive: HUI2 and HUI3), the magnitude of differences
between instruments may be inﬂuenced by sociodemo-
graphic and other factors.
Therefore, the aims of this study were: 1) to char-
acterize the dUTY among four commonly used
preference-based HRQoL instruments: the EQ-5D,
HUI2, HUI3, and SF-6D; 2) to evaluate the potential
impact of these differences on CUA; and 3) to deter-
mine if sociodemographic or other factors inﬂuenced
the magnitude of these differences.
Methods
Study Design and Characteristics of Participants
In this cross-sectional study, consenting Chinese,Malay
and Indian patients and their caregivers recruited from
a primary care facility in Singapore were interviewed by
interviewers of the same ethnicity using a questionnaire
containing the Singapore English, Chinese, Malay and
Tamil versions of the EQ-5D, HUI2, HUI3, and SF-6D
and assessing sociodemographic and other factors
known to inﬂuence HRQoL. Reported standard devia-
tions for the EQ-5D, HUI-3, and SF-6D in various
clinical populations have ranged from 0.18 to 0.35
[17–19]. As our subjects were from a primary care
population, we expected the standard deviations for the
scores to be smaller and estimated it at 0.10. Based on a
CID of 0.04, standard deviation of 0.10, and 80%
power, the sample size required was 99 subjects per
arm. To allow formissing data, we thus aimed to recruit
150 to 200 subjects from each ethnic group. All instru-
ments have [19–21] or are being validated for use in
Singapore [manuscripts in preparation]. Inclusion cri-
teria were 21 years old and above, have ability to
understand English, Chinese, Malay or Tamil as appro-
priate and absence of cognitive impairment (assessed by
the recruiters). Physician-reported acute and chronic
medical conditions were also obtained in this Institu-
tional Review Board-approved study.
Instruments
EQ-5D. The EQ-5D is a generic, preference-based
instrument comprising a health classiﬁcation system
with ﬁve dimensions (mobility, self-care, usual activi-
ties, pain, and anxiety/depression), each with three
response levels (no problem, some problems, severe
problems) and a visual analog scale (EQ-VAS). The
health classiﬁcation system describes a total of 243
health states, each of which is assigned a utility weight,
range from -0.594 to 1, using a utility scoring function
derived from the UK general population using the
Time Trade-Off method [4]. We performed similar
analyses using the US scoring function [22], but did
not present the results here as they were very similar to
those using the UK scoring function. Respondents clas-
siﬁed and rated their health on the day of the survey.
HUI2 and HUI3. The HUI2 and HUI3 consist of
two independent but complementary systems, which
together describe almost 1,000,000 unique health
states. Both instruments include a generic comprehen-
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sive health status classiﬁcation system and a generic
HRQoL utility scoring system, using a utility scoring
function derived from a representative sample of the
Canadian general population using the standard
gamble (SG) and VAS methods [5]. The scores for
HUI2 ranged from -0.03 (worst health state) to 1
(perfect health) and that for HUI3 ranged from -0.36
to 1. The questionnaire used in this study was the
15Q (self-assessment, self-completed version) which
includes items sufﬁcient to classify respondents in both
the HUI2 and HUI3 systems [23,24]. A 4-week recall
period was used.
SF-6D. The SF-6D is a six-dimensional health classi-
ﬁcation system comprising physical functioning, social
functioning, role-limitations, vitality, pain, and mental
functioning, with 4 to 6 levels per dimension, thus
deﬁning a total of 18,000 health states. The utility
weights from 0.29 to 1 for the SF-6D were obtained
using a utility scoring function derived from a repre-
sentative sample of the UK general population using
the SG technique [6].
Family Functioning Measure (FFM). The FFM is a
3-item Likert-type scale validated in Singapore [25],
assessing the quality of interactions among family
members, with higher scores, range from 0 to 100,
reﬂecting better family functioning.
Statistical Analyses
Agreement among preference-based instruments. As
the distribution of utility scores were skewed, we com-
pared differences in patient characteristics and utility
scores among the three ethnic groups completing the
English version of the questionnaires using Kruskal–
Wallis or Friedman’s ANOVA tests for continuous
variables and chi-squared tests for categorical
variables.
To assess agreement between utility scores obtain-
ing using the EQ-5D, HUI2, HUI3, and SF-6D, we
used Bland–Altman (BA) plots [26] of the dUTY (given
by [Y - X]) against the mean utility scores (given by
[(Y + X)/2]) for each pair of instruments. For each
pairwise comparison, the subtractor is listed followed
by the subtrahend. For example, HUI2/EQ-5D denotes
that HUI2 is the subtractor and EQ-5D the subtra-
hend. Data from all language versions were used in this
analysis. This was appropriate as BA plots involved
intraindividual comparisons. Interindividual differ-
ences were not relevant for BA plots in this portion of
the analysis because the focus was dUTY for each
individual subject (rather than between groups of sub-
jects). Although the distributions of utility scores were
skewed, measurement errors (assessed by the BA plot)
were normally distributed [26], thus it was appropriate
to apply BA plots. Bland and Altman argue that such
plots are generally superior to correlation or regression
analyses for determining agreement between different
measurement methods [26]. The degree of measure-
ment agreement for each subject would be reﬂected by
the deviation of dUTY from 0 (where 0 implies total
agreement). The degree of agreement for the entire
group of patients would be reﬂected by the deviation
of the mean dUTY from 0. The CID was used to deﬁne
the magnitude of mean dUTY which would be clini-
cally important. Reported CID for the EQ-5D, HUI2,
HUI3, and SF-6D vary, being 0.074 [27], 0.030 [5],
0.030 [5], and 0.033 [28], respectively. For purposes of
comparison in this study, the CID was therefore
deﬁned as 0.040 points (the average of the four
values). The dUTY between pairs of instruments were
expressed using both means and medians to determine
the inﬂuence of using these summary statistics in sub-
sequent CUA.
Impact of differences in utility estimates on CUA: an
illustration using hypothetical decision trees. To illus-
trate the impact that variability in utility estimates
would have on CUA and its potential impact on
decision-making, we created eight separate hypotheti-
cal decision trees generated using DATA v3.5 (TreeAge
Software Inc., Williamstown, MA, USA) that com-
pared a new drug (Drug B) with an existing drug (Drug
A) for treating the same medical condition. We created
a hypothetical scenario where the incremental cost of
using Drug B over Drug A was US $363,500 for a
complete program in a hypothetical cohort. Although
more expensive, the probability of treatment being
effective was higher for Drug B (0.71) compared with
Drug A (0.16), thus justifying CUA. We then compared
the changes in incremental cost-utility ratio (ICUR)
resulting from differences in the magnitude of utility
estimates from different instruments. We imputed
utility estimates for the base case, and when utility
scores varied by 0.04 points (the CID) or by a quantum
corresponding to the smallest, largest, and the mean of
mean and median dUTY observed in this study. Both
mean and median dUTY were evaluated to provide a
balanced view of the best- and worst-case scenarios. In
general, as distribution of dUTY measured by any two
instruments was normal with a left skew, the mean
dUTY (being larger in magnitude) tended to represent
the worst case scenario. The ICUR was expressed as
the ratio of incremental costs (cost of Drug B minus
cost of Drug A) over incremental QALY (QALY of
Drug B minus QALY of Drug A), with the unit as
$/QALY. The ﬁrst decision tree represented the base
case (Fig. 2). The second decision tree (Table 3) repre-
sented a scenario where utility at each branch of the
decision tree was 0.04 higher than the corresponding
branch in the base case. This corresponded to a situa-
tion where utilities were overestimated by a magnitude
that was clinically important. Other decision trees
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were similarly constructed. We further characterized
second-order uncertainty using Monte Carlo simula-
tions with sampling from utility distributions for the
EQ-5D, HUI2, HUI3, and SF-6D, respectively.
Inﬂuence of sociodemographic factors on dUTY. To
study the inﬂuence of sociodemographic factors on
differences in utility measurement using various pairs
of instruments, we constructed six multiple linear
regression (MLR) models, one for each pair of instru-
ments, using dUTY as the dependent variable. For this
MLR analysis, we used only data from patients who
completed the English version of the HRQoL instru-
ments, as pooling of data from all language versions
would have resulted in a “structural zero” situation,
for example, subjects of Chinese ethnicity, none of
whom spoke Malay, could not have completed a
Malay language questionnaire, which would invalidate
MLR analyses. Data from caregivers were also
excluded in this MLR analysis as important informa-
tion on medical conditions (known to inﬂuence
HRQoL) was not available. Each MLR model was
constructed in two steps. In the ﬁrst, we adjusted for
the inﬂuence of sociodemographic factors such as age,
sex, education, and ethnicity on dUTY for each of the
six pairwise comparisons. We also studied interactions
between education and age, as well as between educa-
tion and ethnicity. Nevertheless, as these were not sig-
niﬁcant, they were not included in the model. In the
second step, we additionally adjusted for the potential
inﬂuences of other patient characteristics such as
marital status, work status, presence of physician-
reported acute and/or chronic medical conditions, and
FFM scores. Positive regression coefﬁcients would
indicate that differences in utility measurement
between the pair of instruments were higher for sub-
jects with that variable of interest than those without.
The reverse would be true for negative regression coef-
ﬁcients. Missing data were handled by list-wise dele-
tion. All statistical analyses were performed using
STATA (Intercooled v.8, STATA Corporation, College
Station, 2003).
Results
Patient Characteristics
Of the 825 subjects approached, 713 participated and
of these, 16 declined to provide sociodemographic
information and 30 had missing HRQoL scores (EQ-
5D: 12; HUI-15Q: 12; SF-6D: 12; 6 subjects had 2
HRQoL scores missing) and were thus excluded from
the analyses. The remaining 667 participants (65%
being patients seeking medical attention) had a median
age of 48 years (range 21–89); 59% were female; 38%
were Chinese, 29% Malay, and 33% Indian, with gen-
erally high utility scores, as would be expected in a
primary care setting (Table 1). Median utility scores
ranged from 0.80 (95% conﬁdence interval [CI] 0.80,
0.85) for the EQ-5D to 0.89 (95% CI 0.88, 0.89)
for the SF-6D, the differences among which were
statistically signiﬁcant (Friedman’s ANOVA, P <
0.001). Median utility scores were not signiﬁcantly
different among the ethnic groups for any of the
instruments.
The English versions of HRQoL instruments were
completed by 142 subjects (39% Chinese, 24% Malay,
and 37% Indian) with a median age of 45 years (range
21–89), 47% being female. There were no statistically
signiﬁcant differences in patient characteristics among
ethnic groups completing the English version of
HRQoL instruments with the exception of Indians
having fewer acute (P = 0.015) or chronic medical con-
ditions (P = 0.026) and Malays having lower family
functioning scores (P = 0.011).
Agreement among Preference-Based Instruments
The BA plots for all six pairwise comparisons among
instruments are given in Figure 1, and the mean and
median dUTY between pairs of instruments are sum-
marized in Table 2. SF-6D scores were generally higher
than EQ-5D, HUI2, or HUI3 scores (dUTY > 0), par-
ticularly at lower utility values. Similarly, HUI3 scores
were generally lower than HUI2 scores, particularly at
lower utility values.
In all pairwise comparisons, at the individual level,
dUTY exceeded the CID for the majority of subjects.
At the group level, mean differences (95% CI)
exceeded the CID of 0.04 for four of six pairwise
comparisons (Table 2), with the exception of the
HUI2/EQ-5D (0.03, CI: 0.02, 0.04) and SF-6D/HUI2
(0.02, CI: 0.006–0.02) comparisons. Interestingly, all
median differences did not exceed the CID of 0.04
(Table 2). In one case (SF-6D/HUI3), however, the
95% CI of median differences contained values that
did exceed the CID of 0.04.
Although large interindividual differences in utility
measurements for each pair of instruments were
observed, a precise estimate of the differences may be
obtained at the group level (Table 2). The width of the
95% CI for mean differences between any pairs of
instruments ranged from 0.02 (SF-6D/HUI2) to 0.03
(HUI3/EQ-5D) while the width of the 95% CI for
median differences between any pairs of instruments
ranged from 0.01 (SF-6D/HUI2) to 0.03 (HUI2/
EQ-5D).
Impact of Differences in Utility Estimates on CUA:
An Illustration Using Hypothetical Decision Trees
We evaluated the impact of dUTY measured using
these instruments on CUA by constructing eight hypo-
thetical models (listed in the Methods section). The
data components of the hypothetical decision trees are
given in Table 3 while their structure is shown in
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Figure 2. In the base-case scenario, the incremental
QALY of using Drug B over Drug A was 3.60, thus
giving an ICUR of US $100,972/QALY. The rationale
for adopting Drug B would change from a weak one to
a moderate one if the ICUR fell below the threshold of
$100,000/QALY [13,29]. The ICUR for each alterna-
tive decision tree (Table 3) ranged from $94,661/
QALY (6.3% difference from base case) to $100,693/
QALY (0.3% difference from base case). In the fourth
decision tree (which gave the largest percent difference
in ICUR from base case of 6.3%), using Monte Carlo
simulations (n = 10,000), the percent difference in
ICUR from the base case ranged from 5.5% to 7.0%.
This suggests that our results are relatively robust.
Inﬂuence of Sociodemographic Factors on dUTY
In MLR models adjusting for age, sex, education, and
ethnicity, none of these variables were associated with
statistically signiﬁcant differences in any of the com-
parisons of pairs of instruments (Table 4). The inﬂu-
ence of education and ethnicity exceeded the CID of
0.04 for three of the instrument pairs (HUI2/EQ-5D,
HUI3/EQ-5D, and SF-6D/HUI3), but these associa-
tions were not statistically signiﬁcant.
In MLR models adjusting for the above sociodemo-
graphic variables and also adjusting for the effects of
other factors including marital status, work status,
presence of acute or chronic medical conditions, and
FFM (Table 4), the presence of chronic medical condi-
tions inﬂuenced the difference in utility scores for
the HUI2/EQ-5D (regression coefﬁcient 0.06,
P = 0.018) and HUI3/EQ-5D pairs (0.08, P = 0.002)
while marital status inﬂuenced dUTY for SF-6D/
EQ-5D (-0.07, P = 0.020), with regression coefﬁcients
exceeding the CID (indicating clinical importance).
FFM scores were also associated with differences
for three instrument pairs (HUI3/EQ-5D [0.03,
P < 0.001], HUI3/HUI2 [0.02, P < 0.001], and SF-6D/
Table 1 Characteristics of subjects and distribution of EQ-5D, HUI2, HUI3, and SF-6D utility scores*
All subjects
(N = 667)
Subjects completing English-language versions (n = 142)
Indian
(n = 53)
Chinese
(n = 55)
Malay
(n = 34) P-value
Age (years)
Median (IQR) 48.0 (37.0, 58.0) 44.0 (35.0, 58.0) 47.0 (33.0, 55.0) 43.0 (29.0, 54.0) 0.51
Mean (SD) 48.2 (15.38) 47.4 (15.77) 45.7 (14.54) 43.2 (15.83) 0.47
Range 21.0 to 89.2 21.1 to 89.2 22.0 to 79.4 21.0 to 79.3
Female 399 (58.9) 27 (50.9) 18 (32.7) 12 (35.3) 0.10
Education (years) 0.29
6 244 (36.0) 8 (15.1) 6 (10.9) 5 (14.7)
7–10 285 (42.1) 30 (56.6) 26 (47.3) 21 (61.8)
11 148 (21.9) 15 (28.3) 23 (41.8) 8 (23.5)
Married 485 (71.6) 42 (79.3) 38 (69.1) 23 (67.7) 0.42
Working 396 (58.5) 33 (62.3) 43 (78.2) 27 (79.4) 0.11
Presence of acute
medical conditions
475 (71.1) 31 (58.5) 45 (81.8) 27 (79.4) 0.02
Presence of chronic
medical conditions
332 (49.6) 21 (39.6) 36 (63.2) 22 (64.7) 0.03
Family Functioning
Measure scores
Median (IQR) 66.7 (50.0, 75.0) 75.0 (50.0, 75.0) 50.0 (43.8, 75.0) 75.0 (50.0, 75.0) 0.12
Mean (SD) 62.9 (22.6) 62.7 (26.63) 56.7 (21.84) 65.0 (16.25) 0.01
Range 0 to 100 0 to 100 0 to 100 25 to 100
EQ-5D
(possible score range: -0.59 to 1)
Median (95% CI) 0.80 (0.80, 0.85) 0.85 (0.80, 0.90) 0.85 (0.83, 1) 0.80 (0.80, 1) 0.69
Mean (SD) 0.82 (0.18) 0.84 (0.17) 0.87 (0.14) 0.86 (0.13) 0.57
Range -0.04 to 1 0.12 to 1 0.41 to 1 0.70 to 1
HUI2
(possible score range: -0.03 to 1)
Median (95% CI) 0.88 (0.87, 0.90) 0.92 (0.87, 0.94) 0.88 (0.85, 0.90) 0.91 (0.87, 0.92) 0.22
Mean (SD) 0.85 (0.14) 0.85 (0.19) 0.84 (0.14) 0.89 (0.08) 0.33
Range -0.11 to 1 0.11 to 1 0.44 to 1 0.72 to 1
HUI3
(possible score range: -0.36 to 1)
Median (95% CI) 0.85 (0.85, 0.85) 0.88 (0.84, 0.92) 0.84 (0.78, 0.89) 0.87 (0.81, 0.92) 0.21
Mean (SD) 0.78 (0.22) 0.79 (0.27) 0.77 (0.23) 0.86 (0.11) 0.17
Range -0.31 to 1 -0.31 to 1 -0.09 to 1 0.60 to 1
SF-6D
(possible score range: 0.29 to 1)
Median (95% CI) 0.89 (0.88, 0.89) 0.89 (0.84, 0.92) 0.89 (0.87, 0.94) 0.85 (0.80, 0.95) 0.85
Mean (SD) 0.87 (0.12) 0.85 (0.13) 0.87 (0.12) 0.87 (0.12) 0.74
Range 0.39 to 1 0.52 to 1 0.39 to 1 0.64 to 1
*n (%) unless otherwise stated.
CI, conﬁdence interval; IQR, interquartile range.
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HUI3 [-0.02, P = 0.003]). Nevertheless, the magni-
tudes of these were less than the CID and may
therefore not be of clinical importance.
Discussion
In this head-to-head comparative study of four
widely used preference-based HRQoL instruments,
we found dUTY obtained using these instruments,
the magnitude of which was clinically important for
several comparisons. These observations are strength-
ened by the use of intrasubject comparisons for
utility scores obtained from these four instruments.
Quantifying dUTY, as in this study, may be used to
make utility data obtained from different instruments
comparable by using an adjustment factor equivalent
to the mean or median dUTY measured by the two
instruments. This creates an exciting possibility of
combining utility scores obtained using different
preference-based instruments (previously discouraged
because of potential biases) and improving precisions
of these pooled estimates used in pharmacoeconomic
analyses. We assessed using hypothetical decision
trees how differences of varying degrees can inﬂuence
 Mean differences in utility scores               Clinically important(lower bound) (-0.04) 
 Linear regression   Clinically important(upper bound) (+0.04) 
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Figure 1 Bland–Altman plots of pairwise comparisons of the EQ-5D, HUI2, HUI3, and SF-6D. For each pairwise comparison, the subtractor is listed
followed by the subtrahend (e.g., HUI2/EQ-5D denotes that HUI2 is the subtractor and EQ-5D the subtrahend).
Table 2 Mean and median differences in utility scores (95% CI) for the EQ-5D, HUI2, HUI3, and SF-6D
Instrument pairs
HUI2/EQ-5D* HUI3/EQ-5D* SF-6D/EQ-5D* HUI3/HUI2 SF-6D/HUI2 SF-6D/HUI3
Mean differences
Mean difference 0.03 -0.04 0.04 -0.07 0.02 0.09
(95% CI) (0.02, 0.04) (-0.06, -0.03) (0.03, 0.06) (-0.08, -0.06) (0.006, 0.02) (0.07, 0.10)
Width of 95% CI 0.02 0.03 0.03 0.02 0.02 0.03
Median differences
Median difference 0.01 -0.03 0.02 -0.03 0.003 0.03
(95% CI) (0, 0.03) (-0.03, -0.003) (0, 0.03) (-0.04, -0.02) (0, 0.01) (0.03, 0.05)
Width of 95% CI 0.03 0.02 0.03 0.02 0.01 0.02
*Mean difference (95% CI) using EQ-5D US scoring algorithm were: HUI2/EQ-5D: -0.01 (-0.02, 0.00007), HUI3/EQ-5D: -0.08 (-0.10, -0.07), and SF-6D/EQ-5D: 0.005 (-0.004,
0.01).
CI, conﬁdence interval.
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the outcomes of CUA, thus highlighting the potential
role for such adjustment factors. We found that, in
general, variation in utility estimates among instru-
ments had a relatively small impact on CUA (range
0.3–6.3%). This suggests that adjustment factors for
different pairs of instruments may not be required in
certain circumstances, for example, if (using our
hypothetical illustration) variation on ICUR of up to
6.3% is acceptable. If not, then an adjustment factor
may need to be applied before pooling utility scores
obtained using different instruments.
That no statistically signiﬁcant associations were
observed between sociodemographic factors and
dUTY between instrument pairs is encouraging
because this simpliﬁes the application of adjustment
factors for pairs of instruments. This also suggests that
these sociodemographic factors may not need to be
taken into consideration when deriving adjustment
factors for pairwise instrument comparisons, and that
these comparisons are therefore likely to be fairly
robust. Nevertheless, as the regression coefﬁcients for
some sociodemographic variables (notably educational
level and ethnicity) exceeded the CID (though not
reaching statistical signiﬁcance), these associations
may be clinically important, and larger studies in a
variety of populations are therefore required to
conﬁrm and further clarify our ﬁndings. Interpretation
of these ﬁndings needs to take into account the fact
that CID may vary among different disease conditions
and is not universal for a given instrument [30]. That
other patient characteristics were found to be associ-
ated with dUTY between instrument pairs in this
exploratory analysis deserves attention. These associa-
tions might be real or spurious (because of the large
number of comparisons) as most of the P-values were
very close to 0.05, with the notable exception of FFM.
The rationale for adjusting for these factors when cal-
culating the adjustment factor needs to be further elu-
cidated, ideally based on a sound theoretical construct.
To the best of our knowledge, this is the ﬁrst head-
to-head comparison of preference-based instruments
in a multiethnic Asian population. Our ﬁndings
Table 3 Data components (utilities and quality-adjusted life-years) and incremental cost-effectiveness ratio (ICER) for 8 hypothetical
decision trees
Variables
Decision tree
1 2 3 4 5 6 7 8
Patients’ utilities for the health
state where the drug
worked (i.e., success)
Drug A 0.700 0.740 0.715 0.785 0.748 0.702 0.733 0.719
Drug B 0.800 0.840 0.815 0.885 0.848 0.802 0.833 0.819
Patients’ utilities for the health
state where the drug
did not work (i.e., failure)
Drug A 0.400 0.440 0.415 0.485 0.448 0.402 0.433 0.419
Drug B 0.500 0.540 0.515 0.585 0.548 0.502 0.533 0.519
QALY
Drug A 2.8 3.03 2.89 3.29 3.08 2.81 2.99 2.91
Drug B 6.4 6.75 6.53 7.13 6.82 6.42 6.69 6.57
Incremental QALY* 3.60 3.72 3.64 3.84 3.74 3.61 3.70 3.66
ICER ($/QALY)† 100,972 97,715 99,863 94,661 97,193 100,693 98,243 99,317
% Difference in ICER
from base case (Tree 1)‡
— 3.2 1.1 6.3 3.7 0.3 2.7 1.6
*Incremental QALY is given by the difference in QALY between drugs A and B.
†ICER is given by the ratio of differences in costs between Drugs A and B over differences in QALY gained by Drugs A and B.A lower ICER is more favorable; incremental cost
of Drug B over Drug A is US $363,500 for all scenarios.
‡Tree 1 represents the base case where probability of treatment success was 0.16 and 0.71 for Drugs A and B, respectively; the number of life-years was 10 if the drug worked
and 5 if the drug did not work.Trees 2–8 represent alternative scenarios where utilities were overestimated by 0.04 (clinically important difference deﬁned a priori), 0.02 (smallest
calculated mean difference), 0.09 (largest calculated mean difference), 0.05 (mean of calculated mean difference), 0.002 (smallest calculated median difference), 0.03 (largest
calculated median difference), and 0.02 (mean of calculated median difference), respectively.
ICER, incremental cost-utility ratio; QALY, quality-adjusted life year.
Effective. Continue.
0.160
QALY = 7.00
Non-effective. Discontinue.
0.840
QALY = 2.00
Drug A 2.80
Effective. Continue.
0.710
QALY = 8.00; P-value = 0.710
Non-effective. Discontinue.
0.290
QALY = 2.50; P-value = 0.290
Drug B 6.40
Disease X
Drug B : 6.40
Figure 2 Structure of the cost-utility decision
tree. Data shown were for base-case scenario.
QALY, quality-adjusted life-year.
262 Wee et al.
Ta
bl
e
4
In
ﬂu
en
ce
of
so
ci
od
em
og
ra
ph
ic
fa
ct
or
s
on
di
ffe
re
nc
es
in
ut
ili
ty
m
ea
su
re
m
en
t
in
pa
ir
w
is
e
co
m
pa
ri
so
ns
of
th
e
EQ
-5
D
,H
U
I2
,H
U
I3
,a
nd
SF
-6
D
am
on
g
su
bj
ec
ts
co
m
pl
et
in
g
th
e
En
gl
is
h-
la
ng
ua
ge
ve
rs
io
ns
H
U
I2
/E
Q
-5
D
H
U
I3
/E
Q
-5
D
SF
-6
D
/E
Q
-5
D
H
U
I3
/H
U
I2
SF
-6
D
/H
U
I2
SF
-6
D
/H
U
I3
R
eg
re
ss
io
n
co
ef
ﬁc
ie
nt
s
P-
va
lu
e
R
eg
re
ss
io
n
co
ef
ﬁc
ie
nt
s
P-
va
lu
e
R
eg
re
ss
io
n
co
ef
ﬁc
ie
nt
s
P-
va
lu
e
R
eg
re
ss
io
n
co
ef
ﬁc
ie
nt
s
P-
va
lu
e
R
eg
re
ss
io
n
co
ef
ﬁc
ie
nt
s
P-
va
lu
e
R
eg
re
ss
io
n
co
ef
ﬁc
ie
nt
s
P-
va
lu
e
A
dj
us
te
d
fo
r
so
ci
od
em
og
ra
ph
ic
fa
ct
or
s
A
ge
(p
er
10
ye
ar
s)
-0
.0
04
0.
66
0.
00
3
0.
79
-0
.0
08
0.
29
0.
00
7
0.
93
-0
.0
1
0.
09
-0
.0
1
0.
29
Fe
m
al
e
-0
.0
1
0.
63
-0
.0
02
0.
96
0.
02
0.
46
0.
01
0.
63
0.
03
0.
16
0.
02
0.
55
Ed
uc
at
io
n
(y
ea
rs
)

6
0.
06
0.
16
0.
05
0.
34
0.
03
0.
42
-0
.0
04
0.
90
-0
.0
3
0.
38
-0
.0
2
0.
62
7–
10
0
0
0
0
0

11
0.
00
4
0.
89
0.
03
0.
47
-0
.0
2
0.
33
0.
02
0.
32
-0
.0
3
0.
22
-0
.0
5
0.
13
Et
hn
ic
ity
In
di
an
0
0
0
0
0
0
C
hi
ne
se
-0
.0
3
0.
38
-0
.0
6
0.
15
-0
.0
06
0.
83
-0
.0
3
0.
19
0.
02
0.
39
0.
05
0.
14
M
al
ay
0.
02
0.
56
0.
04
0.
33
-0
.0
1
0.
74
0.
03
0.
38
-0
.0
3
0.
28
-0
.0
5
0.
18
A
dj
us
te
d
fo
r
so
ci
od
em
og
ra
ph
ic
an
d
ot
he
r
fa
ct
or
s
A
ge
(p
er
10
ye
ar
s)
0.
00
1
0.
50
0.
02
0.
29
-0
.0
00
4
0.
96
0.
00
8
0.
38
-0
.0
08
0.
38
-0
.0
2
0.
24
Fe
m
al
e
-0
.0
07
0.
80
0.
02
0.
56
0.
03
0.
23
0.
03
0.
20
0.
04
0.
11
0.
00
8
0.
82
Ed
uc
at
io
n
(y
ea
rs
)

6
0.
04
0.
30
0.
04
0.
49
0.
01
0
0.
78
-0
.0
05
0.
88
-0
.0
3
0.
33
-0
.0
3
0.
58
7–
10
0
0
0
0
0
0

11
0.
01
0.
67
0.
03
0.
51
-0
.0
18
0.
48
0.
01
0.
59
-0
.0
3
0.
20
-0
.0
4
0.
22
Et
hn
ic
ity
In
di
an
0
0
0
0
0
0
C
hi
ne
se
-0
.0
5
0.
14
-0
.0
6
0.
13
-0
.0
11
0.
67
-0
.0
2
0.
49
0.
03
0.
18
0.
05
0.
17
M
al
ay
-0
.0
03
0.
93
0.
02
0.
72
-0
.0
20
0.
49
0.
02
0.
48
-0
.0
2
0.
53
-0
.0
4
0.
37
M
ar
ri
ed
-0
.0
4
0.
18
-0
.0
6
0.
18
-0
.0
68
0.
02
-0
.0
1
0.
59
-0
.0
2
0.
39
-0
.0
09
0.
82
W
or
ki
ng
-0
.0
3
0.
46
-0
.0
03
0.
94
-0
.0
22
0.
55
0.
02
0.
43
0.
00
3
0.
92
-0
.0
20
0.
65
Pr
es
en
ce
of
ac
ut
e
m
ed
ic
al
co
nd
iti
on
s
0.
04
0.
22
0.
02
0.
64
0.
00
5
0.
86
-0
.0
2
0.
45
-0
.0
31
0.
20
-0
.0
1
0.
71
Pr
es
en
ce
of
ch
ro
ni
c
m
ed
ic
al
co
nd
iti
on
s
0.
06
0.
02
0.
08
0.
02
0.
03
7
0.
11
0.
02
0.
38
-0
.0
3
0.
24
-0
.0
4
0.
17
Fa
m
ily
Fu
nc
tio
ni
ng
M
ea
su
re
sc
or
es
(e
ve
ry
10
po
in
ts
)
0.
00
1
0.
26
0.
03
<
0.
00
1
0.
00
9
0.
08
0.
02
<
0.
00
1
0.
00
2
0.
61
-0
.0
2
0.
00
3
Fo
r
ea
ch
pa
ir
w
is
e
co
m
pa
ri
so
n,
th
e
su
bt
ra
ct
or
is
lis
te
d
fo
llo
w
ed
by
th
e
su
bt
ra
he
nd
(e
.g
.,
H
U
I2
/E
Q
-5
D
de
no
te
s
th
at
H
U
I2
is
th
e
su
bt
ra
ct
or
an
d
EQ
-5
D
th
e
su
bt
ra
he
nd
).
Assessing Differences in Utility Scores 263
provide further support for the literature that equiva-
lence of health utilities obtained using preference-
based instruments cannot be assumed [31]. Our
observation that SF-6D scores were generally higher
than the EQ-5D, HUI2, or HUI3 scores (dUTY > 0)
was also consistent with current literature and may
reﬂect ﬂoor effects associated with SF-36 [12,32]. The
intrasubject comparison of different instruments is
strength of this study, allowing us to investigate agree-
ment between instruments without the potential con-
founding effects of intersubject variations such as
cultural differences in tendencies to report health prob-
lems [33]. Our results showed that despite a wide
range of differences (0.002–0.09) in utility measure-
ments among the instruments, the inﬂuence on ICUR
was marginal (0.3–6.3%). Given that the CID of an
instrument can vary with the clinical population
studied [28], our results are therefore likely to be
robust across different clinical population.
The results of this study need to be interpreted in
the light of several possible limitations. First, we have
assessed differences between instrument pairs using
only cross-sectional data in a primary care population.
As differences in change scores are likely to have a
greater impact on CUA than changes in absolute
scores, the presence and magnitude of differences in
change scores (i.e., sensitivity of instruments) should
be investigated in future longitudinal studies. The gen-
eralizability of our ﬁndings to other clinical popula-
tions also needs investigation. Second, given that
chronic medical conditions appeared to be important
in inﬂuencing differences in utility measurements by
different instruments, the generalizability of our ﬁnd-
ings to other clinical populations (e.g., more severely ill
patients) also needs investigation. Third, we have used
a very simple hypothetical decision tree model to
explore the potential impact of variability in utility
estimates on CUA. Using data from real CUA would
be more informative. Unfortunately, such data were
not available to us. Fourth, the inﬂuence of sociode-
mographic factors and other patient characteristics
with differences in utility measurement could be evalu-
ated only among those subjects completing the
English-language version of the instruments. Further
studies to characterize differences between preference-
based instruments for other language versions would
be needed before researchers can decide if a “univer-
sal” adjustment factor may be applied to different
language versions of the preference-based instruments.
Fifth, as a pragmatic compromise between sample size
and representativeness, we pooled responses from
various language versions of these instruments. We are
aware that this could potentially introduce a system-
atic bias resulting from translation. Nevertheless, it is
encouraging that the equivalence of the English- and
Chinese-language versions of the SF-6D has been pre-
viously demonstrated [34], suggesting that it is pos-
sible to achieve equivalence of the various language
versions of these four widely used instruments. The
equivalence of different language versions of
preference-based instruments should be evaluated in
future studies.
Conclusion
Clinically important differences were found among
four widely used preference-based HRQoL instru-
ments (the EQ-5D, HUI2, HUI3, and SF-6D). The
impact of these differences on CUA appeared to be
relatively minor, but needs further investigation. Socio-
demographic factors including age, sex, education, and
ethnicity did not inﬂuence the magnitude of these
differences. Nevertheless, other patient characteristics
such as presence of chronic medical conditions, marital
status, and FFM inﬂuenced these differences.
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